122 related articles for article (PubMed ID: 34184793)
21. My thoughts on teaching.
Smith BJ
J Vet Med Educ; 2009; 36(3):256-9. PubMed ID: 19861711
[TBL] [Abstract][Full Text] [Related]
22. Virginia okays coverage for experimental cancer coverage.
Tokarski C
J Am Health Policy; 1994; 4(3):57-8. PubMed ID: 10134327
[No Abstract] [Full Text] [Related]
23. Mammography screening after risk-tailored messages: the women improving screening through education and risk assessment (WISER) randomized, controlled trial.
Bodurtha J; Quillin JM; Tracy KA; Borzelleca J; McClish D; Wilson DB; Jones RM; Quillin J; Bowen D
J Womens Health (Larchmt); 2009; 18(1):41-7. PubMed ID: 19105686
[TBL] [Abstract][Full Text] [Related]
24. Bonnie's Bus--cancer disparities in West Virginia, philanthropy and opportunities to build lasting partnerships.
Roth R; Newhouse R; Robinson B; Faulkner S; Remick SC
W V Med J; 2009 Oct; 105 Spec No():68-72. PubMed ID: 19999270
[TBL] [Abstract][Full Text] [Related]
25. The Breast Cancer Prevention Trial (BCPT) in West Virginia.
Jubelirer SJ; Crowell EB
W V Med J; 1992 Sep; 88(9):399-401. PubMed ID: 1462531
[TBL] [Abstract][Full Text] [Related]
26. The subject was breast cancer and informed consent.
Barton S
Va Med; 1982 Nov; 109(11):744-7. PubMed ID: 7180145
[No Abstract] [Full Text] [Related]
27. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
Crespo J; Sun H; Wu J; Ding QQ; Tang G; Robinson MK; Chen H; Sahin AA; Lim B
PLoS One; 2020; 15(11):e0241775. PubMed ID: 33180796
[TBL] [Abstract][Full Text] [Related]
28. Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer.
Xu B; Shen J; Guo W; Zhao W; Zhuang Y; Wang L
Pathol Res Pract; 2019 Feb; 215(2):251-255. PubMed ID: 30420102
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer.
Pu X; Shi J; Li Z; Feng A; Ye Q
Pathol Res Pract; 2015 Jun; 211(6):421-5. PubMed ID: 25818873
[TBL] [Abstract][Full Text] [Related]
30. The West Virginia Cancer Registry: historical development and preliminary results.
Keener B; Jubelirer SJ; German RR; Haddy L
W V Med J; 1995; 91(4):144-6. PubMed ID: 7610648
[TBL] [Abstract][Full Text] [Related]
31. Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment.
Polónia A; Leitão D; Schmitt F
Virchows Arch; 2016 Apr; 468(4):417-23. PubMed ID: 26754674
[TBL] [Abstract][Full Text] [Related]
32. An interview with Dr. Pamela A. Steed. 1997 AAFO Clinician of the Year. Interview by Dr. Craig C. Stoner.
Steed PA
Funct Orthod; 2000; 17(1):4-6, 8-14, 16. PubMed ID: 11307246
[No Abstract] [Full Text] [Related]
33. Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.
Lyman GH; Greenlee H; Bohlke K; Bao T; DeMichele AM; Deng GE; Fouladbakhsh JM; Gil B; Hershman DL; Mansfield S; Mussallem DM; Mustian KM; Price E; Rafte S; Cohen L
J Clin Oncol; 2018 Sep; 36(25):2647-2655. PubMed ID: 29889605
[TBL] [Abstract][Full Text] [Related]
34. Increasing screenings for breast and cervical cancer in West Virginia.
Pearson RJ; Simon K; Pollard C; Frey-McClung V
W V Med J; 1994 Feb; 90(2):50-1. PubMed ID: 8165806
[No Abstract] [Full Text] [Related]
35. A sociodemographic and economic comparison of breast reconstruction, mastectomy, and conservative surgery.
Desch CE; Penberthy LT; Hillner BE; McDonald MK; Smith TJ; Pozez AL; Retchin SM
Surgery; 1999 Apr; 125(4):441-7. PubMed ID: 10216535
[TBL] [Abstract][Full Text] [Related]
36. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
[TBL] [Abstract][Full Text] [Related]
37. Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline.
Brackstone M; Baldassarre FG; Perera FE; Cil T; Chavez Mac Gregor M; Dayes IS; Engel J; Horton JK; King TA; Kornecki A; George R; SenGupta SK; Spears PA; Eisen AF
J Clin Oncol; 2021 Sep; 39(27):3056-3082. PubMed ID: 34279999
[TBL] [Abstract][Full Text] [Related]
38. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
[TBL] [Abstract][Full Text] [Related]
39. Travel distance to mammography and the early detection of breast cancer.
Schroen AT; Lohr ME
Breast J; 2009; 15(2):216-7. PubMed ID: 19292817
[No Abstract] [Full Text] [Related]
40.
Nanoscale Horiz; 2022 Sep; 7(10):1119-1120. PubMed ID: 36106837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
